Want to join the conversation?
$PFE 2Q15 PR: For the third consecutive quarter, the company saw operational revenue growth, excluding the impact of ForEx and despite LOE headwinds. Compared to 2Q14, Eliquis alliance revenues nearly tripled on a global basis and Xeljanz revenues nearly doubled. Prevenar 13 revenue in the US increased 87%.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.